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Adipogenesis Induced by Human Adipose
Tissue–Derived Stem Cells
Wakako Tsuji, M.D.,1 Takashi Inamoto, M.D., Ph.D.,2 Hiroyasu Yamashiro, M.D., Ph.D.,1
Takayuki Ueno, M.D., Ph.D.,1 Hironori Kato, M.D., Ph.D.,1 Yu Kimura, M.Eng.,3
Yasuhiko Tabata, Ph.D., D.Med.Sci., D.Pharm.,3 and Masakazu Toi, M.D., Ph.D.1
Adipose tissue–derived stem cells (ASCs), including preadipocytes, may play an important role in de novo adi-
pogenesis and are expected to be a useful external source of cells for adipose tissue engineering. In this study, we
examined in vivo adipogenesis up to 24 weeks after implantation, induced by human ASCs that were isolated from
adipose tissues and expanded in vitro. ASCs proliferated in vitro in the presence of basic fibroblast growth factor
(bFGF), and the number of cells increased by more than 1000-fold at the fourth passage. The ability to differentiate
into mature adipocytes was maintained up to the third passage. We incorporated designated numbers of third-
passage–expanded cells into a type I collagen scaffold and implanted them into the back of nude mice with or
without controlled-release bFGF. After the implantation of 2106 ASCs with controlled-release bFGF, the greatest
cross-sectional surface area of adipose tissue in the scaffold was 1.19 mm2 at 12 weeks and 2.14 mm2 at 24 weeks.
About 2106 ASCs with controlled-release bFGF was the best condition for total adipogenesis. Immuno-
histochemical analysis with antihuman vimentin antibody showed that the area of human-origin adipose tissue
was maximum in the group with 8106 ASCs incorporated in a scaffold at both 12 and 24 weeks. The amount of
human-origin adipose tissue increased in all groups with implanted ASCs from 12 to 24 weeks. Only trace of
human-origin adipose tissue was observed in other groups implanted ASCs. Our results show that human ASCs
not only function as progenitor cells for in vivo adipogenesis, but also induce de novo adipogenesis for long period.
Introduction
Breast cancer is the most common cancer in women,and surgery remains one of the main treatments. Breast
surgery results in deformity of the breast and negatively
affects patients’ quality of life. Perforator flaps or silicone
implants have been used for breast reconstruction, but each
has advantages and disadvantages. Several trials of autolo-
gous adipose tissue transplantation for breast reconstruction
resulted in a 40–60% reduction in adipose tissue volume be-
cause of insufficient vascularization.1–6
Recent studies in tissue engineering indicate that cell pro-
liferation requires an appropriate cell source, scaffold, and
microenvironment, including growth factors.7,8 The ideal cell
source for tissue engineering must have self-renewal capa-
bility and immunocompatibility.9 Mesenchymal stem cells
(MSCs) isolated from bone marrow stroma can differentiate
into adipogenic, osteogenic, myogenic, and chondrogenic
lineages. However, the procurement of cells from bone mar-
row that are suitable for clinical use has several drawbacks,
including severe pain, morbidity, and a low yield.10 Adipose
tissue–derived stem cells (ASCs) can be isolated from colla-
genase digests of adipose tissue. Various kinds of term have
been used for this cell population, for example, adipose-
derived stem=stromal cells, adipose-derived adult stem cells,
preadipocytes, processed lipoaspirate cells, and adipose mes-
enchymal stem cells. The International Fat Applied Tech-
nology Society reached a consensus to adopt the term
‘‘adipose-derived stem cells’’ to identify the isolated, plastic-
adherent, multipotent cell population.11 ASCs also can
differentiate into adipogenic, osteogenic, myogenic, and
chondrogenic lineages similar to MSCs.12 Moreover, a com-
parison of MSCs and ASCs from the same patient showed no
significant differences in the yield of adherent stromal cells,
growth kinetics, cell senescence, multilineage differentiation
capacity, or gene transduction efficiency.13 Gene array analysis
revealed that less than 1% of genes were differentially ex-
pressed between ASCs and MSCs. ASCs were superior to
MSCs with respect to maintenance of proliferating ability.14
The fraction of preadipocytes contributing to adipogenesis
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differs among species and ages. In humans the fraction is 1% in
children and less than 0.1% in adults.15 Human adipose tissue
is abundant and can be obtained more safely and easily under
local anesthesia or at breast surgery than bone marrow cells.
During differentiation into mature adipocytes, preadipo-
cytes express several types of extracellular matrix (ECM)
proteins, including fibronectin, laminin, and types I, III, IV, V,
and VI collagen. A fibronectin network develops initially, and
a type I collagen network is formed last. These ECMs allow
preadipocytes to differentiate into mature adipocytes.16 In
response to adipogenic stimulation, ASCs form tissue sheets
harboring lipid-filled adipocytes embedded into an abundant
human ECM.17 In vivo adipogenesis depends on the type of
ECM.18 Type I collagen has been widely used as a scaffold for
adipose tissue engineering19–22 because of its porous struc-
ture. Preadipocytes readily adhere to and grow in type I col-
lagen scaffolds.23 An in vitro study reported a higher rate
of adipogenic differentiation with type I collagen than with
fibronectin.24
In vitro proliferation of ASCs is enhanced by basic fibroblast
growth factor (bFGF).25 Although it remains controversial
whether bFGF has direct adipogenic activity,26–29 bFGF has
been shown to promote adipogenesis in vitro and in vivo.30–32
We found that the controlled-release bFGF more effectively
promoted adipose tissue regeneration than aqueous bFGF.20
We have reported that controlled-release 1mg of bFGF=site
was the most effective concentration on adipogenesis 6 weeks
after implantation into nude mice, and a high dose of bFGF
caused the inflammatory response in the collagen scaffold.20
In a previous study, we implanted up to 5105 human
ASCs into nude mice and obtained newly formed adipose
tissue 6 weeks after implantation. However, quantitative and
qualitative differences in the implanted ASCs were not ex-
amined, and not examined for long time. The present study
was therefore investigated the optimal passage number
in vitro and the effects of the number of implanted ASCs on
adipogenesis in vivo over the period up to 24 weeks.
Materials and Methods
Human ASCs
This study was approved by the Kyoto University ethics
committee. Informed consent was obtained from all patients.
All patients were women 29–76 years of age. Samples of hu-
man adipose tissues were obtained as surgical waste tissue at
breast surgery in Kyoto University Hospital (Kyoto, Japan).
Donor samples for in vitro study were obtained from patients
30–76 years of age with a mean age of 58.6 years (n¼ 14). We
allocated seven donors individually to with or without bFGF
treatment group. There was no significance of age between
with and without bFGF treatment groups. Donor samples for
in vivo study were obtained from patients 29–70 years of age
with a mean age of 50.8 years (n¼ 8). All donor samples were
divided equally. ASCs were isolated from the adipose tis-
sue samples as soon as possible after resection by a modifi-
cation of the procedure described by Bjorntorp et al.33 Briefly,
the adipose tissue samples were washed with phosphate-
buffered saline (PBS, pH 7.4) to remove blood cells, minced,
and digested with collagenase (2 mg=mL; Wako Pure Che-
mical, Osaka, Japan) in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) and 20 mg=mL bovine
serum albumin at 378C for 40 min while shaking. The digested
tissue was suspended in DMEM:Nutrient Mixture F-12(Ham)
(1:1) (DMEM=F-12) containing 10% heat-inactivated fetal bo-
vine serum (FBS), penicillin (100 U=mL), and streptomycin
(0.1 mg=mL) (basal medium). The suspension was filtered
through a 250-mm nylon mesh and centrifuged at 400 g for
10 min at 208C. The sediment was suspended in basal me-
dium, placed in 10-cm tissue culture dishes (Falcon; Falcon,
New York, NY), and cultured in a humidified atmosphere of
95% air and 5% CO2 at 378C for 1 day. The dishes were gently
washed with PBS to remove nonadherent cells and filled with
the basal medium and cultured until the adherent ASCs be-
came confluent (P0:Passage0). Then ASCs were detached with
1% trypsin-EDTA solution (Sigma, St. Louis, MO).
Proliferation ability of ASCs
ASCs were suspended in the basal medium, placed in 10-
cm tissue culture dishes or 96-well microtiter plate (Falcon)
at the density of 1.0104 cells=cm2, and cultured with
100 ng=mL bFGF or without bFGF for 1 week.34 To evaluate
proliferative activity, viable cells in each dish were counted
by the trypan blue dye exclusion method at the end of cul-
ture. These numbers represent the proliferation of undiffer-
entiated ASCs. The proliferation of ASCs was also evaluated
by MTT assay.35 Using a commercially available kit for MTT
assay (Chemicon International, Temecula, CA), we spectro-
photometrically measured the absorbance of the solution
mixture in each well at 570–630 nm.
Differentiation ability of ASCs
ASCs suspended in basal medium were placed in 24-well
plates (Falcon) at a density of 1.0105 cells=cm2 and cultured
for 1 day. The medium was then changed to DMEM=F-12
medium (1000mL=well) containing 0.05 mM insulin, 0.2 nM
3,5,3-triiodothyronine, 100 nM transferrin, 17 mM calcium
pantotenate, 33 mM biotin, and 100 nM dexamethasone (ITT
medium)36 and cultured for 21 days. To evaluate adipogenic
differentiation of ASCs, glycerol-3-phosphate dehydrogenase
(GPDH) activity was measured using a commercially avail-
able kit (GPDH activity measurement kit, JFL003; Hokudo,
Hokkaido, Japan).37 ASCs were washed twice with PBS and
homogenized in the buffer solution included with the kit,
using a handy sonic homogenizer (UR-20; Tomy Seiko, To-
kyo, Japan) on ice. After mixing, the absorbance of the solu-
tion mixture was spectrophotometrically measured at 340 nm.
Materials
We prepared a disc form of type I collagen scaffold (di-
ameter, 20 mm; height, 2.5 mm) and gelatin microspheres
(isoelectric point, 5.0), as described in our previous report.20,38
An aqueous solution of human recombinant bFGF was kindly
supplied by Kaken Pharmaceutical, Tokyo, Japan. Other
chemicals were purchased from Wako Pure Chemical In-
dustries, Kyoto, Japan, and used without further purification.
To prepare controlled-release bFGF, 2 mg of gelatin micro-
spheres was swollen with an aqueous solution of bFGF (20 mL,
containing 1mg of bFGF) and allowed to stand at 378C for 1 h.
Implantation of ASCs
Animal experiments were reviewed by the Committee on
the Ethics of Animal Experiments (Faculty of Medicine,
84 TSUJI ET AL.
Kyoto University, Kyoto, Japan) and were carried out in
accordance with the Guidelines for Animal Experiments of
the Faculty of Medicine, Kyoto University.
The designated number of third-passage ASCs (0: A group
and B group; 5105: C group and D group; 2106: E group
and F group; 8106: G group and H group) were incor-
porated into the collagen scaffolds with (B, D, F, and H
groups) or without controlled-release bFGF (A, C, E, and G
groups), and implanted subcutaneously into the back of 6-
week-old female BALB=c nude mice (Shimizu Laboratory
Supply, Kyoto, Japan) under general anesthesia. Twelve-
week group consisted of five mice. Twenty-four-week group
consisted of three mice. Twelve and 24 weeks after im-
plantation, the mice were euthanized with an overdose of
anesthesia, and the implanted sites including the skin (ap-
proximately 22 cm2) were carefully removed for subse-
quent histological examinations.
De novo adipogenesis and human ASC–derived
adipogenesis
One half of each tissue specimen was fixed in 10% neu-
tralized formalin solution and embedded in paraffin. Sections
(thickness, 2mm) of the specimens were stained with hema-
toxylin and eosin (H-E). The other half of the specimen was
frozen, and sections were stained with oil red O to confirm the
presence of mature adipose tissue. Paraffin sections were
stained with a monoclonal antibody against human vimentin
(mahv, clone V9, Code Nr. M 0725 Lot 057; DAKO, Glostrup,
Denmark). The antibody was used at a dilution of 1:25. The
positive control was human adipose tissue, and the negative
control was murine adipose tissue. Adipose tissue area of the
scaffolds and the human vimentin–positive area were mea-
sured and analyzed with the computer program Image-Pro
Plus (Media-Cybernetics, Bethesda, MD). We took pictures of
H-E sections with Axio Vision (Carl Zeiss MicroImaging
GmbH, Go¨ttingen, Germany) software, and opened these
pictures with Image-Pro Plus. We measured the area of scaf-
folds and newly formed adipose tissue with the manual
measurement function. Scaffolds were stained with H-E, but
lipid droplets were not stained. We excluded fibroblastic
capsules around the scaffolds. Morphologically, collagen
scaffolds have a net-like structure, adipose tissue has a gran-
ulated structure, and fibroblastic capsules have a layered
structure. The average area of the scaffolds was 2.14 mm2 and
did not differ significantly among the groups.
Statistical analysis
The Mann–Whitney U-test (Microsoft Exel, Statcel2) was
employed for statistical analysis, and p< 0.05 was consid-
ered to indicate statistical significance.
Results
Proliferative activity of ASCs
The proliferative activity of the ASCs in vitro was retained
through the 10th passage as assessed by the viable cell count
(Fig. 1) and MTT assay (Fig. 2). The proliferative activity of
the ASCs was 1.6–4.0-fold higher in the presence of bFGF
than in the absence of bFGF (Fig. 1). The number of ASCs
increased by more than a 1000-fold at the fourth passage of
ASCs cultured with bFGF. Statistically significance was seen
in the presence of bFGF (Figs. 1 and 2). There was no cor-
relation between the proliferative activity of the ASCs and
age of donors.
Differentiation of ASCs to mature adipocytes
Differentiation of ASCs to mature adipocytes as assessed
by GPDH activity assay was observed at all passages (Fig. 3).
The extent of differentiation of ASCs in the presence of bFGF
was greater than that in the absence of bFGF from the first to
third passages, and decreased from the fourth passage on-
ward. From first to third passage, differentiation of ASCs in
the presence of bFGF was significantly greater than any other
groups. Open and closed bars at start show intrinsic GPDH.
There was no correlation between the extent of differentia-
tion and age of donors.
FIG. 1. Proliferation of ASCs in vitro assessed on the basis
of the viable cell count. The number of viable ASCs per 10 cm
of the tissue culture dish after culture with 100 ng=mL bFGF
(open bars) or without bFGF (closed bars) for 1 week was
measured by trypan blue dye exclusion assay. *: p< 0.05
versus without bFGF group.
FIG. 2. Proliferation of ASCs in vitro as assessed by MTT
assay. Proliferation of ASCs in 96-well microtiter plates cul-
tured with 100 ng=mL bFGF (open bars) or without bFGF
(closed bars) for 1 week was measured by MTT assay.
*: p< 0.05 versus without bFGF group.
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Adipogenesis of implanted human ASCs
On the basis of the in vitro data described above, we im-
planted the designated number of third-passage ASCs cul-
tured with bFGF into the back of 6-week-old female BALB=c
nude mice. The ASCs were incorporated into the collagen
scaffolds with or without controlled-release bFGF. In all the
groups, adipogenesis was induced in the scaffold and main-
tained up to 24 weeks after implantation (Figs. 4-1 and 4-2).
The greatest cross-sectional surface area of adipose tissue in
the scaffold was 1.19 mm2 12 weeks after implantation, which
was equivalent to 68.84% of the scaffold area. In contrast, the
adipose tissue area was 0.58 mm2 in the group receiving a
scaffold alone (without ASCs) with controlled-release bFGF
(B group) (Fig. 5-1). In the group receiving 2106 ASCs in-
corporated in a scaffold without controlled-release bFGF (E
group), the adipose tissue area was 0.40 mm2. The area of
adipose tissue was 0.08 mm2 in the group receiving a scaffold
alone (A group). The extent of adipogenesis in the group
receiving 2106 ASCs incorporated in a scaffold without
controlled-release bFGF (E group) was similar to that in the
group receiving a scaffold alone with controlled-release bFGF
(B group). In the group receiving 8106 ASCs in a scaffold
without controlled-release bFGF (G group), adipogenesis in
the scaffold decreased to the level of the group receiving a
scaffold alone (A group). At 24 weeks, the total adipose tissue
area increased in most of the groups (Fig. 5-2). The greatest
cross-sectional surface area of adipose tissue in the scaffold
was 2.14 mm2 in the F group, which was almost twice as
that at 12 weeks. In the group receiving 8106 cells with-
out controlled-release bFGF (G group), total adipogenesis
was greater than de novo adipogenesis (A and B groups).
Controlled-release bFGF thus had statistically an additive
effect on adipogenesis in most of the groups at both 12 and 24
weeks.
Human ASC–derived adipogenesis
Human vimentin–positive cells were found in all the
groups receiving ASCs. Most of these cells were not mature
adipocytes. However, at 12 weeks, in the group receiving
8106 ASCs in a scaffold with controlled-release bFGF (H
group), human ASC–derived mature adipocytes were ob-
served (Fig. 6). The extent of human ASC–derived adipo-
genesis in the H group 12 weeks after implantation was
equivalent to 14.6% of total adipogenesis in the scaffold. In
contrast, the extent of human ASC–derived adipogenesis in
other groups was less than 1% (Fig. 7-1). At 24 weeks, human
ASC–derived adipose tissue area was increased in all the
groups receiving ASCs (Fig. 7-2). The greatest cross-sectional
surface area of human-derived adipose tissue in the scaffold
was 0.35 mm2 in the group receiving 8106 ASCs in a scaffold
without controlled-release bFGF (G group), and this was
43.8% of total adipose tissue area. In the H group, human-
derived adipogenesis was 0.17 mm2, which was equivalent to
44.4% of total adipogenesis in the scaffold.
Discussion
ASCs are similar to MSCs13 and proliferate considerably
when cultured with bFGF.39,40 We isolated 5105 ASCs from
5 g of fresh adipose tissue obtained during breast cancer
surgery. We considered 5105 ASCs were scarce as a starting
material for adipogenesis in vivo, and proliferated with bFGF
ex vivo. Heimburg et al. showed that 8104 to 3.5105 pre-
adipocytes can be harvested from 1 g of fresh adipose tissue,
depending on the donor and the method used for cell re-
trieval.41 ASCs are isolated from excised or aspirated adipose
tissue. Lipoaspiration from the abdominal wall requires an-
other incision site and is associated with further pain. More-
over, informed consent would have to be additionally
received for this procedure. It is therefore not suitable for our
study. We used excised adipose tissue obtained during breast
surgery in this study. The adipose tissue is usually discarded
after operation, and informed consent is readily obtained.
Viable cells from adipose tissue decrease with preservation
conditions and time periods after resection.42 We usually
preserve resected adipose tissue at 48C and isolate ASCs as
soon as possible after resection to minimize cell damage. We
had probatively isolated ASCs 72 h after surgery and obtained
about half the number of ASCs from 5 g of adipose tissue.
In this study, we did not exclude patients with axillary
lymph node metastasis or advanced stage, and cancer cells
might remain in breast or axillary adipose tissue. However,
we did not see any cancer cells in ASCs cultured in vitro for
10 weeks and in the adipose tissues in vivo for 24 weeks after
implantation. In the future, the procedure should be clini-
cally performed in carefully selected patients to avoid cancer
cell dissemination.
When cultured with 100 ng=mL of bFGF, ASCs proliferated
more than 1000-fold at the fourth passage, whereas the ability
of ASCs to differentiate into mature adipocytes decreased
subsequently. Two reasons may account for this phenome-
non. First, the ‘‘stem cell’’ population decreases and other pop-
ulations of cells, such as fibroblasts, increase after the fourth
passage. Stem cells are characterized by self-renewal capacity,
long-term viability, and multilineage potential. The stem cell–
associated marker CD34 was at peak levels in the stromal
vascular fraction cells and early passage ASCs throughout the
FIG. 3. Adipogenic differentiation of ASCs. GPDH activity
of ASCs at each passage after culture with 100 ng=mL bFGF
(open bars) or without bFGF (closed bars) for 1 week and
incubation in DMEM=F-12 medium containing insulin, 3,5,3-
triiodothyronine, transferrin, calcium pantotenate, biotin, and
dexamethasone for 21 days was measured using a commer-
cially available GPDH activity measurement kit and a spec-
trophotometer (absorbance of the solution mixture at 340 nm
per minute). *: p< 0.05 versus without bFGF group and the
group passages 4–10.
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FIG. 4-1. Adipogenesis of implanted human ASCs 12 weeks after implantation. The designated number of third-passage
ASCs cultured with bFGF (0: A, B; 5105: C, D; 2106: E, F; 8106: G, H) and incorporated into collagen scaffolds with (B, D,
F, H) or without controlled-release bFGF (A, C, E, G) were implanted into the back of 6-week-old female BALB=c nude
mice. Formation of adipose tissue in the implanted scaffold 12 weeks after implantation is indicated by the arrows
(magnification100). Scale bar¼ 100 mm. Color images available online at www.liebertonline.com=ten.
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FIG. 4-2. Adipogenesis of implanted human ASCs 24 weeks after implantation. The designated number of third-passage
ASCs cultured with bFGF (0: A, B; 5105: C, D; 2106: E, F; 8106: G, H) and incorporated into collagen scaffolds with (B,
D, F, H) or without controlled-release bFGF (A, C, E, G) were implanted into the back of 6-week-old female BALB=c
nude mice. Formation of adipose tissue in the implanted scaffold 24 weeks after implantation is indicated by the arrows
(magnification100). Scale bar¼ 100mm. Color images available online at www.liebertonline.com=ten.
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culture period.43,44 Second, because the ASCs were cultured in
medium containing 10% FBS, bFGF expression was progres-
sively lost, leading to impaired self-renewal ability.45 To ob-
tain ASCs that retain the ability to differentiate into mature
adipocytes, ASCs should optimally be cultured with bFGF
until the third passage. A previous study has reported that
human adipose tissue–derived MSCs retain their capacity to
differentiate into mature adipocytes (GPDH activity) for least
15 passages.46 However, peak GPDH activity is at the fifth
passage. These findings are consistent with our results.
De novo adipogenesis occurs without implanting
ASCs,19,31,32,47–49 because preadipocytes are recruited from
surrounding adipose tissue and differentiate into mature
adipocytes. Ideally, adipose tissue engineering techniques
would simulate this phenomenon after breast surgery in the
future. In women with breast cancer, however, less ASCs
would survive at the implantation site of ASCs incorporated
in a collagen scaffold with controlled-release bFGF, because
the conserved breast usually receives radiation therapy after
breast conserving surgery.50 Because de novo adipogenesis is
unlikely, we require exogenous progenitor cells. Implanted
progenitor cells are expected to differentiate into mature
adipocytes. Cell implantation therapy has some benefits, and
ASC-assisted lipotransfer has been used for cosmetic breast
augmentation.51 Clinically, the implantation of ASCs in-
cluding preadipocytes is prerequisite to a successful outcome
of adipose tissue engineering.
One of our objectives was to confirm how many mouse-
derived cells can be recruited and how many human-derived
cells must be implanted. We immunohistochemically distin-
guished human-origin from mouse-origin adipose tissue with
the use of antihuman vimentin antibody. Vimentin is not
specific for preadipocytes or adipocytes, but it is expressed on
these cells. Franke et al. concluded that lipid droplets are
FIG. 5-2. Adipose tissue area
in the scaffolds 24 weeks after
implantation. The designated
numbers of third-passage
ASCs incorporated into scaf-
folds with (open bars) or
without controlled-release
bFGF (closed bars) were im-
planted into the back of 6-
week-old female BALB=c
nude mice. The adipose tissue
area in the scaffolds was
measured and analyzed with
the computer program Image-
Pro Plus. *: p< 0.05 versus
without controlled-release
bFGF and group A.
FIG. 5-1. Adipose tissue
area in the scaffolds 12 weeks
after implantation. The
designated numbers of third-
passage ASCs incorporated
into scaffolds with (open bars)
or without controlled-release
bFGF (closed bars) were im-
planted into the back of 6-
week-old female BALB=c
nude mice. The adipose tissue
area in the scaffolds was
measured and analyzed with
the computer program Image-Pro Plus. The average area of the scaffolds was 2.14 mm2 and did not differ significantly among
the groups. *: p< 0.05 versus without controlled-release bFGF and group A.
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encaged in a vimentin-containing structure.52 The antihuman
vimentin antibodies used to confirm newly formed adipose
tissue were human derived in many in vivo studies.20,22,53,54
We previously reported that human-derived adipocytes were
distinguishable from de novo adipocytes with antihuman
vimentin staining.20 In our study, structures around lipid
vacuoles were stained with antihuman vimentin antibody,
indicating the presence of human-derived mature adipocytes.
No human vimentin–positive cells were found in the groups
receiving a scaffold alone, with or without controlled-release
bFGF (A and B groups). At 12 weeks, in the group receiving
2106 ASCs with controlled-release bFGF (F group), the hu-
man vimentin–positive area was accounted for less than 1% of
newly formed adipose tissue. And in the group receiving
8106 ASCs with controlled-release bFGF (H group), the
human vimentin–positive area was equivalent to about 15%
of newly formed adipose tissue. At 24 weeks, human-derived
adipose tissue area increased in every group. In the F group,
the human vimentin–posiive area was 2.8% of newly formed
adipose tissue. In the H group, the human vimentin–positive
area was equivalent to 44.4% of newly formed adipose tissue.
Both human adipose tissue area and percentage of the scaffold
were increased from 12 to 24 weeks in the H group. Human
ASCs take longer time to differentiate into mature adipocytes
than mouse ASCs. Implanted human ASCs differentiate into
mature adipocytes in the host and continue to differentiate for
a long time. At 24 weeks in the G group, human-derived
adipogenesis was 0.35 mm2, while de novo adipogenesis was
0.45 mm2 and greater than the A group. From this result,
implanted human ASCs not only differentiate into mature
adipocytes but also promote de novo adipogenesis. Implanted
human ASCs function for a long time as progenitor cells for
in vivo adipogenesis and induce de novo adipogenesis.
An optimal cell seeding concentration for scaffold forma-
tion may exist. Our results suggested that 2106 ASCs=site
was the best concentration at both 12 and 24 weeks. At 12
weeks, in the group receiving 2106 ASCs incorporated in a
scaffold without controlled-release bFGF (E group), the area
of newly formed adipose tissue was similar to that in the
group receiving the scaffold alone with controlled-release
bFGF (B group). Although bFGF has an obvious effect on
adipogenesis, the number of implanted cells is also an im-
portant factor. Heimburg et al. seeded 106 preadipocytes cul-
tured in the medium supplemented with epidermal growth
factor onto collagen sponges, which were then implanted
into mice. They found that implantation of a large number of
preadipocytes is important for the promotion of adipogen-
esis.22 Torio-Padron et al. injected human ASCs in fibrin into
nude mice and also concluded that an increased cell concen-
tration enhances the formation of adipose tissue.55 However,
FIG. 6. Human ASC–derived adipogenesis. Immunohis-
tochemical sections of newly formed adipose tissue 12 and
24 weeks after implantation. Human-origin adipose tissue
is stained by antihuman vimentin antibody. Group receiv-
ing 2106 ASCs with controlled-release bFGF at 12 weeks
(F), group receiving 8106 ASCs with controlled-release
bFGF at 12 weeks (H), and group receiving 8106 ASCs with
controlled-release bFGF (H) at 24 weeks (magnification
200). Scale bar¼ 100mm. Color images available online at
www.liebertonline.com=ten.
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from our data, there might be the best cell concentration for
total adipogenesis. Both 12 and 24 weeks after implantation,
maximum adipose tissue area was observed in the group re-
ceiving 2106 ASCs with controlled-release bFGF (F group),
not in the group receiving 8106 ASCs (G and H groups).
Implanted ASCs not only differentiate into mature adipo-
cytes, but also secrete ECM to promote maturation. The
amount of ECM or cytokines secreted by ASCs may increase
with an increased number of implanted ASCs and produce
an appropriate micromilieu for proliferation and differentia-
tion of ASCs themselves. Stillaert et al. reported that ASCs
secrete additional ECM components and that these ECM
components were able to act as inductive factors to further
enhance adipogenesis in vivo.56 In our study, 2106 ASCs
with controlled-release bFGF (F group) might be the optimum
condition in terms of secreted ECM, cytokines, and succeed-
ing cell survival. Implanting 8106 ASCs (G and H groups)
was not good condition for total adipogenesis. The number
of ASCs that can survive in the scaffold might be limited.
Since there are many inflammatory cells in the specimens
of the G and H groups, some of 8106 ASCs are supposed to
be dead. The dead cells might cause inflammation and in-
hibit differentiation into mature adipocytes. Only in the H
group at 24 weeks, bFGF did not have additive effects for
both total and human-derived adipogenesis. Total adipo-
genesis decreased, but human-derived adipogenesis in-
creased in the H group. Too many ASCs might inhibit de novo
adipogenesis.
In summary, our results indicate that the implantation of
optimum number of ASCs with controlled-release bFGF is the
key for a successful outcome of functional adipose tissue en-
gineering for long term. Newly formed adipose tissue in-
duced by human ASCs fully matured and functioned for a
long time. There are few papers that report in vivo human-
derived adipogenesis for such a long period as our paper. This
study is baseline for future clinical practice. Further studies
are needed to discover the most efficient ways of generating
adipose tissue for clinical practice.
FIG. 7-1. Human vimentin–
positive area in the scaffolds 12
weeks after implantation. The
designated number of third-
passage ASCs cultured with
bFGF incorporated into the
scaffolds with (open bars) or
without controlled-release
bFGF (closed bars) were im-
planted into the back of
6-week-old female BALB=c
nude mice. The human
vimentin–positive area in the
scaffolds was measured and
analyzed with Image-Pro Plus.
*: p< 0.05 versus any other
group.
FIG. 7-2. Human vimentin–
positive area in the scaffolds
24 weeks after implantation.
The designated number of
third-passage ASCs cultured
with bFGF incorporated into
the scaffolds with (open bars)
or without controlled-release
bFGF (closed bars) were
implanted into the back of 6-
week-old female BALB=c
nude mice. The human
vimentin–positive area in
the scaffolds was measured
and analyzed with Image-Pro
Plus. *: p< 0.05 versus groups
C and D.
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